Public Employees Retirement Association of Colorado Has $1.01 Million Stake in Exact Sciences Corporation (EXAS)
Public Employees Retirement Association of Colorado cut its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 9.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,389 shares of the medical research company’s stock after selling 2,194 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Exact Sciences Corporation were worth $1,008,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. BlackRock Inc. lifted its stake in Exact Sciences Corporation by 45,816.0% in the 1st quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock valued at $160,718,000 after buying an additional 6,789,478 shares in the last quarter. Fred Alger Management Inc. purchased a new position in Exact Sciences Corporation in the 2nd quarter valued at about $84,177,000. Lord Abbett & CO. LLC lifted its stake in Exact Sciences Corporation by 59.1% in the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after buying an additional 875,527 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Exact Sciences Corporation in the 2nd quarter valued at about $29,450,000. Finally, Vanguard Group Inc. lifted its stake in Exact Sciences Corporation by 8.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after buying an additional 700,051 shares in the last quarter. Hedge funds and other institutional investors own 85.65% of the company’s stock.
A number of research analysts recently weighed in on the stock. Robert W. Baird lowered shares of Exact Sciences Corporation from an “outperform” rating to a “neutral” rating and set a $56.00 price target on the stock. in a research note on Monday. Zacks Investment Research lowered shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BTIG Research lowered shares of Exact Sciences Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 1st. Bank of America Corporation raised their price target on shares of Exact Sciences Corporation from $56.00 to $58.00 and gave the company a “buy” rating in a research note on Tuesday, October 31st. Finally, Canaccord Genuity raised shares of Exact Sciences Corporation to a “buy” rating and set a $60.00 price target on the stock in a research note on Tuesday, October 31st. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $49.71.
In other news, SVP D Scott Coward sold 29,115 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now owns 64,991 shares in the company, valued at approximately $3,064,975.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas D. Carey bought 2,500 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The stock was bought at an average price of $37.71 per share, with a total value of $94,275.00. Following the acquisition, the director now directly owns 60,858 shares in the company, valued at approximately $2,294,955.18. The disclosure for this purchase can be found here. Insiders have sold a total of 277,373 shares of company stock valued at $12,635,570 in the last 90 days. Insiders own 4.00% of the company’s stock.
Shares of Exact Sciences Corporation (NASDAQ EXAS) opened at $60.37 on Monday. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $63.60.
Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.07. The business had revenue of $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business’s revenue was up 158.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.36) EPS. analysts expect that Exact Sciences Corporation will post -1.14 earnings per share for the current fiscal year.
WARNING: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/13/public-employees-retirement-association-of-colorado-has-1-01-million-stake-in-exact-sciences-corporation-exas.html.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.